drugset / Trial / NCT00763022
Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects.
Timeline
- Start
- 2003-11
- Primary completion
- 2004-12
- Completion
- 2004-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMIGLITAZAR | Small molecule | 16 mg | Oral |
| Subject | IMIGLITAZAR | Small molecule | 32 mg | Oral |